araag2/HINT huggingface dataset:
Clinical trial NCT00329082 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: ly2062430, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  At least 50 years of age and diagnosed with mild to moderate Alzheimer's disease or
             healthy volunteers

          -  fluent in reading and speaking English

          -  AD patients must have a reliable study partner who will be in frequent contact with
             the patient and comply with protocol requirements

          -  AD patients who have received AChEIs or memantine for at least 4 months and on stable
             therapy for at least 2 months prior to starting study drug

        Exclusion Criteria:

          -  Have a history of serious infectious disease affecting the brain, head trauma, cancer,
             drug or alcohol abuse in the past 5 years

          -  Have serious or uncontrolled health problems or laboratory tests

          -  Multiple or severe drug allergies

          -  Prior participation in an active immunization study
Clinical trial NCT00673439 (phase 2, status: terminated)
Conditions: heparin-induced thrombocytopenia
ICD codes: D75.82
Drugs: fondaparinux, warfarin
SMILES: CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O, S1SSSSSSS1
Reason stopped: 
    study terminated due to low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  high risk for HIT based on "Four Ts score" of 6 or more

        Exclusion Criteria:

          -  pulmonary emboli at the time of enrollment

          -  arterial thrombosis at the time of enrollment

          -  limb threatening phlegmasia cerulea dolens at the time of enrollment

          -  Calculated Creatinin Clearance less than 50 ml/hr

          -  platelet count less than 50

          -  Weight less than 50 kg

          -  pregnancy

          -  allergy to fondaparinux

          -  bacterial endocarditis

          -  history of neuraxial anesthesia and post-operative indwelling epidural catheter

          -  active major bleeding (hemodynamically significant or requiring transfusions)

          -  inability to give informed consent
Clinical trial NCT00661778 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: bevacizumab, cisplatin, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, ≥ 18 years of age.

          -  Stage IIIb or IV non-small cell lung cancer.

          -  Chemotherapy-naive.

        Exclusion Criteria:

          -  Previous treatment for non-small cell lung cancer.

          -  Previous malignant tumor within last 5 years, except for basal cell skin cancer or
             preinvasive cervical cancer.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to start of study.

          -  Recent or current chronic treatment with aspirin (> 325 mg/day).
Clinical trial NCT00126451 (phase 2, status: terminated)
Conditions: breast cancer, colorectal cancer, non-small-cell lung carcinoma
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, D02.20, D02.21, D02.22
Drugs: mk0683, vorinostat, suberoylanilide hydroxamic acid (saha), duration of treatment - during each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must be 18 years or older with confirmed diagnosis of breast adenocarcinoma,
             colorectal carcinoma or non-small cell lung cancer

          -  Patients must have relapsed or refractory disease following at least one
             chemotherapeutic treatment regimen.

          -  Has a measurable, positron emission tomography (PET) assessable lesion

          -  Adequate blood, liver, bone marrow and kidney functions

          -  Has not received any chemotherapy for at least 4 weeks prior to entry in this study

          -  Agrees to take adequate measures to prevent pregnancy.

        Exclusion Criteria:

          -  Patient has had prior treatment with histone deacetylase (HDAC) inhibitor.

          -  Patient has had treatment with investigational agents within the last 30 days.

          -  Patient has active infection or had intravenous (IV) antibiotic, antiviral, or
             antifungal medications within 2 weeks of the start of study drugs.

          -  Patient has HIV, hepatitis B or hepatitis C infection.

          -  Patient is pregnant or lactating.

          -  Patient has allergy to any component of the study drug.
Clinical trial NCT00470418 (phase 2, status: completed)
Conditions: alzheimer disease, dementia
ICD codes: G30.8, G30.9, G30.0, G30.1, G31.09, G31.83, F01.50, F01.51, F03.90, F03.91, F18.17
Drugs: nic5-15, placebo
SMILES: CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  NINCDS/ADRDA criteria for probable AD

          -  MMSE between 12-27

          -  Treatment with a cholinesterase inhibitor or an NMDA (N-methyl-D-asparate) antagonist
             with stable dose for at least 12 weeks

          -  Home monitoring available for supervision of medications

          -  Caregiver available to accompany patient to all visits and willing to participate in
             study as informant

          -  Fluent in English or Spanish

          -  Medical stability for this study as confirmed by review of records, internist's
             physical exam, neurological exam, and laboratory tests

          -  Stable doses of non-excluded medication

          -  No evidence of hepatic insufficiency

          -  Able to swallow oral medications

          -  Ability to participate in the informed consent process

        Exclusion Criteria:

          -  History of Diabetes Mellitus (OGTT criteria) requiring treatment with an excluded
             antidiabetic medication (see below) or history of hypoglycemia

          -  Active hepatic or renal disease

          -  Cardiac disease including history of congestive heart failure or current treatment for
             CHF; history of recent myocardial infarction

          -  Use of another investigational drug within the past two months

          -  History of clinically significant stroke

          -  History of seizure or head trauma with disturbance of consciousness within the past
             two years

          -  Major mental illness including psychotic disorders, bipolar disorder, or major
             depressive episode within the past two years Medication Exclusion

          -  Current use of oral hypoglycemic agents including sulfonylureas and meglintinides

          -  Current use of a lipid-lowering agent (excluded from Study #1, see discussion below)

          -  Current or past treatment with insulin for longer than two weeks

          -  Current use of drugs with significant anticholinergic or antihistaminic properties
Clinical trial NCT01152385 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: azd1656, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  women of non-childbearing potential.

          -  Provision of informed consent prior to any study specific procedures

          -  Naïve T2DM patients with HbA1c ≥ 7.5% but ≤ 10% or T2DM Patients treated with one or
             two oral anti-hyperglycaemic agent(s) with HbA1c ≥ 7.5% but ≤ 9.5% at enrolment visit
             (Visit1)

        Exclusion Criteria:

          -  Clinically relevant medical history or concurrent disease such as cardiovascular
             disease, renal disease, hepatic disease and haematological disease.

          -  The investigator(s) judged that the Subject should not participate in the study
             according to screening test or medical history.

          -  Participation in another clinical trial and/or intake of another investigational drug
             within the last 30 days prior to enrolment visit
Clinical trial NCT02162979 (phase 2, status: terminated)
Conditions: parkinson's disease
ICD codes: G20
Drugs: sildenafil, placebo
SMILES: CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    not enough subjects.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of idiopathic Parkinson's disease, Hoehn and Yahr stage 2.0 to 4.0.

          2. Presence of drug-induced dyskinesias

          3. Age>40 years.

          4. Willingness and ability to comply with the study requirements and give informed
             consent.

        Exclusion Criteria:

          1. Atypical parkinsonian syndrome due to drugs, metabolic disorders, encephalitis, or
             degenerative diseases.

          2. History of stereotaxic brain surgery.

          3. Clinical history of dementia.

          4. Known major psychiatric disorder, major depression, schizophrenia. Known alcoholism or
             substance dependence within previous 12 months.

          5. History of major hematological, renal, or hepatic abnormalities.

          6. Known coronary artery disease including angina or myocardial infarction within the
             last 6 months. Significant cardiovascular disease including cardiac failure, unstable
             angina or life-threatening arrhythmia within the last 6 months.

          7. History of stroke within the last 6 months.

          8. Abnormal EKG consistent with cardiac ischemia.

          9. Treatment with nitrates. Nitrates or any NO donors in any dosage form (oral,
             sublingual, transdermal, inhalation, or aerosols).

         10. Malignant hypertension or SBP . 180 or <90, or DBP .110 or <50.

         11. History of priapism.

         12. Known history of retinitis pigmentosa.

         13. Positive pregnancy test.

         14. History of bleeding disorder.

         15. Patients with active peptic ulcer disease associated with bleeding.

         16. Unwillingness to use adequate contraceptive methods if of childbearing potential.

         17. Patients with medical or psychological condition or social circumstances that would
             impair their ability to participate in the study.

         18. Use of Viagra or any experimental drugs within 30 days of screening visit.
Clinical trial NCT00120198 (phase 2, status: terminated)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cdop plus rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 65 years and older;

          -  Diagnosis of Non-Hodgkin's lymphoma where therapy with CHOP plus rituximab is
             considered;

          -  Previously untreated;

          -  ECOG 0-2

          -  Adequate renal and hepatic functions;

          -  Cardiac ejection fraction at least 50% by MUGA. No significant cardiac abnormalities
             by EKG;

          -  Signed informed consent

        Exclusion Criteria:

          -  CNS involvement by lymphoma;

          -  Hypersensitivity to study drugs;

          -  Active infection;

          -  Prior treatment with monoclonal antibodies for cancer;

          -  History of cardiac disease with New York Heart Association Class II or greater or
             clinical evidence of congestive heart failure
Clinical trial NCT00796861 (phase 2, status: terminated)
Conditions: ascites
ICD codes: R18.0, R18.8, K70.10, K70.11, K70.30, K70.31, K71.50
Drugs: sunitinib
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Reason stopped: 
    phycisican decided to terminate study due to slow patient accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Solid tumor malignancy and failure of at least one biologic or cytotoxic regimen, or
             the inability to receive standard treatment due to performance status (PS>2).

          -  Ascites based on paracentesis or CT scan within one month prior to enrollment

          -  Life expectancy > 3 months

          -  Indwelling paracentesis catheters are permitted, paracentesis is permitted at the
             investigators discretion

          -  Negative urine pregnancy test for females

          -  All subjects must agree to use birth control

          -  All subjects must abstain from eating grapefruit and grapefruit juice. They must tell
             their physicians about any changes in their medication including over-the-counter and
             herbal supplements.

        Exclusion Criteria:

          -  History of congestive heart failure

          -  Creatinine > 2.0

          -  Pregnant or nursing

          -  ALT > 2.5 times the upper limit of normal

          -  Blood pressure > 160/90 (antihypertensives permitted)

          -  Gastrointestinal or intra-abdominal hemorrhage within the last 6 months

          -  History of QTc > 450 milliseconds

          -  Brain metastasis
Clinical trial NCT01010581 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: sc12267 (4sc-101), placebo, methotrexate, folic acid
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1
Eligibility criteria:

        Main Inclusion Criteria:

          -  Patients with active RA of functional classes I, II or III according to the criteria
             of American Rheumatism Association for RA

          -  DAS28(ESR) ≥ 4.5 (DAS28 formula with 4 variables using ESR)

          -  Patients who have received weekly doses of MTX (10-25 mg/week) for a minimum of 3
             months prior to Day 1 dosing, and who have received a stable MTX dose of 10-25 mg/week
             without any change in route or change in folic acid supplementation for at least 6
             weeks prior to Day 1 dosing

          -  Patients may receive up to 10 mg/day of oral prednisolone or steroid equivalent. Dose
             must have been stable for at least 30 days and must not be changed during the washout,
             screening and treatment periods, unless dictated by tolerability requirements

        Main Exclusion Criteria:

          -  Patients with RA of functional classes IV according to the criteria of American
             Rheumatism Association for RA

          -  Patients who have received any of the following treatments must abide by the indicated
             washout period:

               1. Leflunomide requires a 6 month washout period prior to Day 1 dosing

               2. Oral or injectable gold, azathioprine, penicillamine, anakinra require a 30 day
                  washout period prior to Day 1 dosing

               3. Cyclosporine, abatacept, etanercept, adalimumab, infliximab, and rituximab
                  require a 60 day washout period prior to Day 1 dosing

               4. Cyclophosphamide requires a 180 day washout period prior to Day 1 dosing

               5. Parenteral or intra-articular corticosteroids require a 30 day washout period
                  prior to Day 1 dosing

          -  Receipt of the following drugs within 4 weeks prior to dosing:

               1. Sulfasalazine

               2. Hydroxychloroquine

               3. Use of corticosteroids > 10 mg/day
Clinical trial NCT00559741 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fluorouracil, irinotecan hydrochloride, leucovorin calcium
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed colorectal cancer

               -  Advanced or metastatic disease

          -  Scheduled to receive first- or second-line therapy for metastatic disease

          -  No cerebral metastases or symptomatic or uncontrolled meningeal disease

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  ANC ≥ 2,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Total bilirubin ≤ 2 times upper limit of normal (ULN)

          -  AST and ALT ≤ 3 times ULN

          -  Alkaline phosphatase ≤ 5 times ULN

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No intestinal blockage

          -  No complete dihydropyrimidine dehydrogenase deficiency

          -  No chronic inflammatory disease of the colon

          -  No other cancer except for nonmelanoma skin cancer or curatively treated carcinoma of
             the cervix or breast

          -  No other severe condition, or condition that is likely to worsen, including any of the
             following:

               -  Unstable heart disease

               -  Myocardial infarction within the past 6 months

               -  Active uncontrolled infection

          -  No contraindication to atropine

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from prior anticancer therapy

          -  More than 4 weeks since prior and no other concurrent investigational therapy

          -  Prior adjuvant chemotherapy allowed

          -  No prior fluorouracil or irinotecan hydrochloride

          -  No other concurrent anticancer therapy
Clinical trial NCT00412919 (phase 2, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: azacitidine
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosis of MM as per IMWG criteria

          -  age greater than 17 years

          -  have received at least 2 but no more than 4 prior lines of therapy

          -  have failed to respond to the most recently administered anti-MM therapy or have
             demonstrably progressive disease as defined by accepted standard criteria

          -  have a life expectancy of at least 3 months

          -  ECOG performance status < 3

          -  at registration haematological values within the following limits:

               1. absolute neutrophil count (ANC) > 1.0 x 109/L

               2. platelet count > 50 x 109/L unsupported

          -  At registration biochemical values within the following limits

               1. Bilirubin < 1.5 x upper limit of normal (ULN) and transaminases < 2 x ULN unless
                  considered secondary to hepatic myelomatous infiltration

               2. Serum creatinine < 0.19mMol/L

          -  Written informed consent

          -  Must agree to use adequate contraceptive measures if indicated. Specifically, women of
             childbearing potential (WOCBP) may participate provided they meet the following
             conditions:

               1. Agree to use at least 2 effective contraceptive methods throughout the study and
                  for 30 days following the study

               2. Have a negative serum pregnancy test within 24 hours of commencing on study
                  medication

               3. Male participants with female partners that are WOCBP must agree to use 2
                  effective contraceptive methods throughout the study and for 30 days following
                  the study

        Exclusion Criteria:

          -  Patients with monoclonal gammopathy of undetermined significance (MGUS) or
             indolent/smouldering MM

          -  Known or suspected hypersensitivity to AZA or mannitol

          -  Patients whose general condition makes them unsuitable for intensive treatment e.g.
             significant cardiac or pulmonary disease

          -  Active infections or other illnesses that precludes chemotherapy administration or
             patient compliance

          -  Active viral infection with known human immunodeficiency virus (HIV) or viral
             hepatitis type B or C

          -  Pregnant or lactating women
Clinical trial NCT00280683 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: l-arginine, placebo
SMILES: [N]=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Moderate to severe persistent asthma

          -  Subject is stable on same asthma medications for at least one month

          -  If the subject is a woman of child-bearing age, a negative pregnancy test

        Exclusion Criteria:

          -  Less than 18 yrs/ age

          -  Baseline Forced Expiratory Volume in 1 second (FEV1) <40% predicted

          -  Known or suspected allergy to L-arginine

          -  Pregnant women, nursing women, or women actively trying to achieve pregnancy

          -  Current smokers

          -  Subjects with more than a 15 pack-year history of smoking
Clinical trial NCT01387347 (phase 2, status: completed)
Conditions: dry eye syndrome, dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: thymosin beta 4, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Have given a written, informed consent.

          2. Be able and willing to follow instructions, including participation in study
             assessments, and be present for the required study visits for the duration of the
             study.

          3. Have a best corrected visual acuity.

          4. Have a patient-reported history of dry eye in both eyes.

          5. Use and/or desire to use an artificial tear substitute for dry eye symptoms within the
             past 6 months.

          6. A negative urine pregnancy test if female of childbearing potential.

          7. Have a corneal fluorescein staining score of ≥ 2 in any corneal surface segment in at
             least one eye at Visit 1.

             -

        Exclusion Criteria:

          1. Have contraindications to the use of the study drug.

          2. Have known allergy or sensitivity to the study drug or components thereof.

          3. Have anterior blepharitis.

          4. Be diagnosed with an on-going ocular infection or active ocular inflammation.

          5. Use contact lenses within 1 week before Visit 1 or during the course of the study.

          6. Have previously had Laser-Assisted in Situ Keratomileusis (LASIK) surgery within 12
             months prior to Visit 1.

          7. Be currently taking any topical ophthalmic prescription or over-the-counter (OTC)
             solutions, artificial tears, gels, or scrubs and cannot discontinue these medications
             for the duration of the trial.

          8. Have used topical ocular cyclosporine within 30 days prior to Visit 1.

          9. Have had a past or present evidence of malignancy.